The DEA has shared its final 2023 research drug production quotas and is now targeting further manufacturing targets for several psychedelic compounds the already significant increases with regard to 2022 initially proposed reported marijuana moment.

The compounds include Marijuana, MDMA, Psilocyn, LSD, Mescaline, 5-MeO-DMT, MDA and 2-CB.

The Agency specified that it is “committed to ensuring an adequate and uninterrupted supply of controlled substances to meet U.S. estimated legitimate medical, scientific, research and industrial needs, for lawful export requirements, and for the establishment and maintenance of back-up stockpiles. ”

Thus, production quotas for 2023 would increase for Psilocyn from originally 8,000 grams to 12,000 grams, 5-MeO-DMT from 6,000 to 11,000 grams, MDMA from 8,200 to 12,000 grams, MDA from 200 to 12,000 grams and 2-CB from 25 to 5,100 grams .

In the case of marijuana, the DEA proposed producing 6.7 million grams — or 14,770 pounds — for medical and scientific use, more than double what it will be in 2022. Licensed growers can now apply to become state marijuana suppliers to become the National Institute on Drug Abuse (NIDA.)

Several companies have already made recommendations to increase DEA’s proposed 2023 quotas for pre-clinical and clinical research, specifically for PTSD, TRD, schizophrenia and anxiety.

The proposal also received comment regarding the creation of “diversified categories” for the production and research of psilocybin-containing mushroom fruiting bodies/sclerotia/liquid cultures similar to cannabis (flower), fruiting body extract (similar to cannabis extract), and psilocybin and psilocyn separately as purified compounds (similar to Delta -9-THC) and applying the same system to mescaline and other plants, fungi, and life forms that produce these compounds.

However, the agency responded that the proposals “do not affect the analysis involved in setting” production quotas…